Ottawa Nephrology
Ottawa Nephrology
  • 72
  • 70 056
Kidney Disease Epidemiology with Dr Eric Weinhandl
Learning Objectives:
To describe US trends in incidence and the prevalence of end-stage kidney disease (ESKD), as well as trends in utilization of home dialysis and kidney transplantation
To forecast the incidence of ESKD, on the basis of trends in care patterns among patients with non-dialysis-dependent chronic kidney disease (CKD)
To assess the strength of evidence that federal policy is modifying long-term secular trends in the cost of care for CKD and ESKD
Dr. Eric D. Weinhandl, PhD, MS, is an epidemiologist who was introduced to nephrology as an undergraduate student in 2001. Eric is a long-time co-investigator at the United States Renal Data System (USRDS), a registry that is operated by the Chronic Disease Research Group in Minneapolis, under the auspices of the National Institutes of Health. During the 2010s, Eric worked in a variety of capacities with NxStage Medical, the manufacturer of a widely used home hemodialysis device in the US. More recently, Eric worked at Satellite Healthcare, a California-based dialysis provider that historically managed between 20% and 25% patients on home therapies. In August 2023, Eric joined DaVita Clinical Research, where he serves as the Vice President of Epidemiology. Eric resides in Minnesota with his wife, Sarah; four children; two dogs; and for now, a crayfish named Pickle.
มุมมอง: 72

วีดีโอ

The Topsy-Turvy approach to CVD in Kidney Transplant with Prof Adnan Sharif
มุมมอง 18114 วันที่ผ่านมา
Learning Objectives: Review the epidemiology of cardiovascular disease for kidney failure patients before and after transplantation. Understand the limitations of current post-transplant management of cardiovascular disease. Critically appraise the current practice of screening asymptomatic kidney transplant candidates for cardiac disease. Prof. Adnan Sharif graduated from the University of Edi...
The Lupus Nephritis Classification: Lost in Translation with Dr. William Whittier
มุมมอง 406หลายเดือนก่อน
Learning Objectives: Discuss the history of lupus nephritis and how the classifications have changed over time. Review why the classification needs to change. Review how the classification should change from the perspective of a clinical nephrologist. Dr. William Whittier is a Professor of Medicine in the Division of Nephrology at Rush University Medical Center in Chicago and a practicing Clini...
Pregnancy with CKD with Dr. Kate Wiles
มุมมอง 411หลายเดือนก่อน
Learning Objectives: To be able to counsel about the risks of adverse obstetric and renal outcomes in pregnancy in females with CKD To understand key aspects of care in pregnancy for females with CKD To understand the complexity of a diagnosis of superimposed pre-eclampsia Dr. Kate Wiles is as a consultant nephrologist and obstetric physician at Barts Health NHS Trust, London, UK. She is the le...
Contemporary concepts in acute kidney injury and the journey to personalised care with Dr Emily See
มุมมอง 3612 หลายเดือนก่อน
Learning Objectives: 1. To define the phenotypes of acute kidney injury 2. To understand current acute kidney injury management 3. To describe the link between pathophysiological mechanism and potential therapies Dr. Emily See is a Consultant Intensivist and Nephrologist at the Royal Melbourne Hospital, a Senior Honorary Fellow at the University of Melbourne, and an Adjunct Senior Research Fell...
mir-486-5p For Acute Kidney Injury And Vascular Outcomes with Dr Adrianna Douvris
มุมมอง 1482 หลายเดือนก่อน
Learning Objectives: 1. MicroRNAs and acute kidney injury 2. miR-486-5p for AKI, the transition to CKD, and vascular outcomes in rats 3. Effect of miR-486-5p in cultured endothelial cells Dr. Adrianna Douvris completed her MD at the University of Toronto, and Internal Medicine and Nephrology residencies at the University of Ottawa. After clinical training, she pursued a PhD in Cellular and Mole...
Hyponatremia Correction with Dr Harish Seethapathy
มุมมอง 1.1K5 หลายเดือนก่อน
Learning Objectives: Deeply explore the evidence supporting the current guidelines for correction rates in hyponatremia Recognize the implications and potential adverse effects associated with various correction rates Dr. Harish Seethapathy is a Clinician-Educator in the Division of Nephrology at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School in ...
RCTs of Dietary Interventions in CKD with Dr Dylan MacKay
มุมมอง 2915 หลายเดือนก่อน
Learning Objectives: At the end of this session, participants will be able to: Explain why we need more RCTs in nutrition and CKD. Describe how the potential renal acid load equation can be used to “dose” fruit and vegetables intake for metabolic acidosis. Consider that all source of dietary potassium are not equal in terms of impact on blood potassium concentrations. Dr. Dylan MacKay, PhD is a...
Personalized Risk-based management of IgA Nephropathy
มุมมอง 3855 หลายเดือนก่อน
Learning Objectives: To review population-level data on the incidence of GN, the risk of cardiovascular disease and the risk of infections To describe personalized risk stratification in IgAN and the use of proteinuria as a surrogate outcome in IgAN Dr. Sean Barbour Bio: I completed my internal medicine and nephrology training at the University of British Columbia (BC) in 2010. I subsequently d...
Oral Anticoagulation for Atrial Fibrillation in Dialysis with Ziv Harel
มุมมอง 6725 หลายเดือนก่อน
Learning Objectives: To highlight why managing atrial fibrillation is important and discuss its epidemiology in patients receiving dialysis. To demonstrate that equipoise exists in the current management strategies for atrial fibrillation in patients receiving dialysis. To describe the results of a pilot trial comparing different anticoagulation strategies in atrial fibrillation patients receiv...
Rare Genetic Variants to Kidney Disease with Dr Alex Chang
มุมมอง 2026 หลายเดือนก่อน
Learning Objectives: Describe the genotypic and phenotypic spectrum of ADPKD Improve recognition of potentially undiagnosed Alport Syndrome in patients with hematuria and proteinuric kidney disease Understand differences in prevalence and severity of genetic kidney diseases in the general population vs. disease-focused cohorts As a physician-scientist, practicing nephrologist, and acting co-Dir...
Frailty Assessment in CKD with Dr Andrew Nixon
มุมมอง 2826 หลายเดือนก่อน
Dr. Andrew Nixon is a Consultant Nephrologist and Supportive Care Lead in the Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust and Honorary Lecturer at the University of Manchester, UK. Andy graduated in 2009 from the University of Edinburgh. He was awarded a PhD by the University of Manchester in 2021 for his thesis: ‘Frailty Assessment and Intervention in Chron...
Acute Kidney Injury Risk Classification and Phenotyping, with Dr Javier Neyra
มุมมอง 6187 หลายเดือนก่อน
Dr. Javier Neyra graduated from the Universidad Peruana Cayetano Heredia Medical School in Lima, Peru (MD degree), and completed postgraduate training in Internal Medicine at Henry Ford Hospital (Detroit, Michigan) and in Nephrology and Clinical Research (Master of Science in Clinical Sciences) at UT Southwestern Medical Center (Dallas, Texas). After serving on the Faculty as Director of Critic...
Estimating GFR: Facts and Fiction with Dr Pierre Delanaye
มุมมอง 6957 หลายเดือนก่อน
Dr. Pierre Delanaye, MD, PhD 50 years old, who is working at the University Hospital of Liège in Belgium. His daily practice is the care of dialysis patients (acute and chronic). His topics of research are: estimating and measuring GFR, definition and epidemiology of CKD, frailty in dialysis patients, CKD-MBD biomarkers​ ​Learning Objectives:​ how estimating GFR in 2024 ? ​ Limitations of estim...
Obesity in the Patient with CKD: Mechanisms to Management​ with Dr Evan Zeitler
มุมมอง 5357 หลายเดือนก่อน
Dr. Evan Zeitler is a nephrologist-scientist interested in better understanding the mechanisms underpinning the effects of obesity on the kidney. His work focuses on understanding how kidney cell metabolism changes in response to high caloric intake and increased adiposity, with the hopes of discovering new pathways involved in the development of obesity related kidney disease. He is a practici...
The Aging Kidney with Dr Andrew Rule
มุมมอง 7498 หลายเดือนก่อน
The Aging Kidney with Dr Andrew Rule
Urinary Sediment Microscopy ​for Kidney Disease Diagnosis with Dr JC Velez
มุมมอง 6558 หลายเดือนก่อน
Urinary Sediment Microscopy ​for Kidney Disease Diagnosis with Dr JC Velez
Hepatorenal Syndrome with Dr Juan Carlos Velez
มุมมอง 1.5K8 หลายเดือนก่อน
Hepatorenal Syndrome with Dr Juan Carlos Velez
Dialysate Bicarbonate Concentration: A Tricky Balancing Act, with Dr Amber Molnar
มุมมอง 5999 หลายเดือนก่อน
Dialysate Bicarbonate Concentration: A Tricky Balancing Act, with Dr Amber Molnar
Pitfalls and Promise of Alerts for AKI and Beyond, with Dr Perry Wilson
มุมมอง 2949 หลายเดือนก่อน
Pitfalls and Promise of Alerts for AKI and Beyond, with Dr Perry Wilson
Dialysis Access with Dr Fawad Qureshi, Mayo Clinic
มุมมอง 8059 หลายเดือนก่อน
Dialysis Access with Dr Fawad Qureshi, Mayo Clinic
Kidney Biopsies in Deceased Donors: Friend or Foe? Dr S. Ali Husain
มุมมอง 32210 หลายเดือนก่อน
Kidney Biopsies in Deceased Donors: Friend or Foe? Dr S. Ali Husain
The Four Pillars of Managing Diabetic Kidney Disease with Dr Brendon Neuen
มุมมอง 3.5K11 หลายเดือนก่อน
The Four Pillars of Managing Diabetic Kidney Disease with Dr Brendon Neuen
One Day Kidney Donor Evaluation, with Dr Bugeja
มุมมอง 16811 หลายเดือนก่อน
One Day Kidney Donor Evaluation, with Dr Bugeja
Gout and Chronic Kidney Disease
มุมมอง 1K11 หลายเดือนก่อน
Gout and Chronic Kidney Disease
Revisiting Aldosterone: New Perspectives on Hypertension & Cardiorenal Health with Dr. J. Brian Byrd
มุมมอง 1.2Kปีที่แล้ว
Revisiting Aldosterone: New Perspectives on Hypertension & Cardiorenal Health with Dr. J. Brian Byrd
Patient Decision Support in Chronic Kidney Disease with Dr Meghan Elliott
มุมมอง 340ปีที่แล้ว
Patient Decision Support in Chronic Kidney Disease with Dr Meghan Elliott
Non-adherence in Hypertension with Dr Indranil Dasgupta
มุมมอง 320ปีที่แล้ว
Non-adherence in Hypertension with Dr Indranil Dasgupta
Patient Reported Outcomes: Strategies for use in Dialysis with Prof Kara Schick-Makaroff
มุมมอง 182ปีที่แล้ว
Patient Reported Outcomes: Strategies for use in Dialysis with Prof Kara Schick-Makaroff
Update on Membranous Nephropathy with Dr Tiffany Caza
มุมมอง 1.4Kปีที่แล้ว
Update on Membranous Nephropathy with Dr Tiffany Caza

ความคิดเห็น

  • @haysamrady8732
    @haysamrady8732 หลายเดือนก่อน

    rules are gold

  • @Remanche1
    @Remanche1 2 หลายเดือนก่อน

    Do nothing: kidneys heal when the body heals/sepsis resolves and hemodynamics improve:)

  • @gopalakrishnagandikota1083
    @gopalakrishnagandikota1083 2 หลายเดือนก่อน

    What would be the risk of oxalate nephropathy when using vit c and ways to avoid if any

  • @PabloGarcia-yw8oo
    @PabloGarcia-yw8oo 2 หลายเดือนก่อน

    Excellent talk

  • @il3mendo
    @il3mendo 3 หลายเดือนก่อน

    High glutamine/ glutamic acid ( Gad 65 ) ?

  • @il3mendo
    @il3mendo 3 หลายเดือนก่อน

    Low zinc sign of diabetes 1 mellitus/gastrointestinal malabsortion ?

  • @kanchanchakraborty7781
    @kanchanchakraborty7781 4 หลายเดือนก่อน

    Hello my daughter have xlinked alport syndrome 1 is she is hearing from 50 db in right ear, ledt is fine...is this cause kidney issue in both ? On one kidney? Whixh medicine is suitable for her

  • @-TheOracle-
    @-TheOracle- 5 หลายเดือนก่อน

    AFIB has been on the rise globally. A huge jump in cases of AFIB across the globe was in the year 2020. G5 began to deploy in 2018 and world wide in 2019 In 2020 , G5 is in every hands of cell phone owners. AFIB rates have surged worldwide, notably spiking in 2020 alongside the widespread deployment of G5 technology. This significant increase in AFIB could indicate a potential correlation between the two. Either that or it might be my gas station sushi I had last night.

  • @foletto
    @foletto 6 หลายเดือนก่อน

    👍🏻👍🏻👍🏻👍🏻👍🏻👍🏻👍🏻👍🏻👍🏻

  • @ahtishamshakoormd
    @ahtishamshakoormd 6 หลายเดือนก่อน

    Excellent talk on a difficult topic

  • @foletto
    @foletto 7 หลายเดือนก่อน

    Super !!! 👏🏻👏🏻👏🏻👏🏻

  • @sorianasor9730
    @sorianasor9730 8 หลายเดือนก่อน

    very bad explanation

  • @willischambers8417
    @willischambers8417 8 หลายเดือนก่อน

    🤷 'PromoSM'

  • @ttantawy60
    @ttantawy60 8 หลายเดือนก่อน

    excellent presentation

  • @deepakk7067
    @deepakk7067 9 หลายเดือนก่อน

    morbidly obese with BMI >40 - feel femoral has multiple issues - just going to be moist once the pannus falls back on the catheter post placement, more issues with kinking and need to keep the leg straight. agree planning for a future access but no one size fits all. More obese - more likely IJ

  • @khaled3470
    @khaled3470 9 หลายเดือนก่อน

    Sorry my question is it convenient to remove temporary line and insert permcath during bactreamia? As our center refused until culture becomes negative

  • @Rene-uz3eb
    @Rene-uz3eb 10 หลายเดือนก่อน

    Long term use of Ace inhibitors cause severe damage to the kidneys as shown in a recent study, especially when already hypoxic. Most women are asymptomatic in the more common XLAS, so the risk of Ace inhibitor damage is probably much higher than potential benefit in that group. Since at birth the basement membranes use a different fetal collagen 112 network, not only in Alport disease, I wonder if those are just more susceptible to iron like in other fetal/nonfetal cell diseases. 21:16 indeed she just said it. Yep, serum iron reduces collagen production, so presumably in particular a1a1a2, and increases MMP: Effect of free iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells, 2002 17:44 this bell curve is much too wide. The 95% confidence interval is at most 40-60% for x inactivation at 100-200 embryo cells, which should hold also at tissue level. So the right side is very rare. 29:48 to update recommendations based on a handful of patients is absolutely ridiculous, in particular when it involves a very mild form of the disease that wasn't even included in the trial. I thought panels always scream for more data. The non randomized arm with slightly larger numbers did not even show a statistically significant difference, and an endpoint of proteinuria is hardly what matters 34:40 people should really be told that you should not exercise 48 hours before a proteinuria test. I believe the recommendation is 24h. Exercise dramatically raises protein in urine many fold even after 30 hours. 39:53 bardoxolene basically is just a patentable version of oleanic acid (olive oil). The trial was successful increasing egfr. Yet the fda wanted to 'see more data' and denied drug app. Oleanic acid also activates nrf2, and has been shown before to improve ckd. So this seems to work pretty well then, olive oil that is, in Alport. A similar compound was shown to reduce fibrosis, and bardoxolene was shown to improve pulmonary hypertension in connective tissue disease. 41:33 more patients were actually dropped because of elevated liver tests. These, like proteinuria, can be elevated, for over a week after exercise so maybe the people on the trial just felt better and worked out. The patients with more complications were in the placebo group.

  • @thomasbrown5648
    @thomasbrown5648 11 หลายเดือนก่อน

    I am 41years old. My gfr is 84. My urine is very foamy. My dna report shows homozygous variants on my col4a4 gene. My doctor said i have no blood or protein in my urine

  • @jiyugu
    @jiyugu 11 หลายเดือนก่อน

    Can SGLT2i be used for patients with minimal change disease using cyclosporine?

  • @jamalalwakeel161
    @jamalalwakeel161 11 หลายเดือนก่อน

    Thank you very much excellent comprehensive lecture

  • @futureiscoming5925
    @futureiscoming5925 ปีที่แล้ว

    Thank you for this excellent talk❤

  • @themcmichaelchang
    @themcmichaelchang ปีที่แล้ว

    Very informative. Thank you!

  • @laneicewatson3196
    @laneicewatson3196 ปีที่แล้ว

    Sean go book Julia help

  • @hassanhabeeb5168
    @hassanhabeeb5168 ปีที่แล้ว

    Excellent work

  • @Arun-mh7br
    @Arun-mh7br ปีที่แล้ว

    I am afraid of neurological damage due to dialysis Please help

  • @arelhawkinberry6288
    @arelhawkinberry6288 ปีที่แล้ว

    👌 "Promo SM"

  • @MahavirBafna01
    @MahavirBafna01 ปีที่แล้ว

    Sir i am suffering by alport syndrome since childhood I am 19 now I had by kidney transplant 1.6 years ago and i am fine now After my transplant my hearing loss is decreased from 62% to 53% and i wear specs now

  • @abdelhamed012
    @abdelhamed012 ปีที่แล้ว

    With Rituximab treatment will follow C/D 19 count or serum IgG levels and when to replace

  • @abdelhamed012
    @abdelhamed012 ปีที่แล้ว

    Aza or MMF for maintenance if Rituximab not available

  • @abdelhamed012
    @abdelhamed012 ปีที่แล้ว

    Other B cell depletion therapy like Benlysta or obitunuzumab in vasculitis and atacicept or telitacicept

  • @abdelhamed012
    @abdelhamed012 ปีที่แล้ว

    Effect of avacopan on ANCA titer

  • @bhanupratapsingh-ln9of
    @bhanupratapsingh-ln9of ปีที่แล้ว

    CKD stage 4 creatinine levels 3.25

  • @hardik4u24
    @hardik4u24 ปีที่แล้ว

    Does risk of tma recurrence increase in patient with related live donor transplant ?

  • @hardik4u24
    @hardik4u24 ปีที่แล้ว

    Very good class …

  • @andrewramos1542
    @andrewramos1542 2 ปีที่แล้ว

    💘 pքɾօʍօʂʍ

  • @goodexams3064
    @goodexams3064 2 ปีที่แล้ว

    Is there a role of S/V in HFpEF? Does it reduces weight on starting s/v via natriuresis?

  • @hashimawan2433
    @hashimawan2433 2 ปีที่แล้ว

    So you're saying SGLT2 is Good for the Kidneys ??????

    • @paulabrown5243
      @paulabrown5243 ปีที่แล้ว

      Yes, for chronic kidney disease.

  • @mondorecording
    @mondorecording 2 ปีที่แล้ว

    I am a transplanted person who has had covid late December 21, would I now have natural immunity

    • @ottawanephrology
      @ottawanephrology 2 ปีที่แล้ว

      yes you would have an element of natural immunity - but natural immunity is not durable (ie wanes with time) and may not be protective to all variants out there.

  • @shubharthidr
    @shubharthidr 3 ปีที่แล้ว

    Great TALK!!!

  • @algheriani2902
    @algheriani2902 3 ปีที่แล้ว

    👍